Conclusions Our data indicate that H. pylori infection increases ACVR1 expression, promoting gastric IM via regulating CDX2, which is an essential step in H. pylori carcinogenesis.

**IDDF2021-ABS-0123** STREPTOMYCES PLURIPOTENS MUSC 135T AS A TREASURE TROVE FOR ANTI-COLON CANCER AND ANTI-MRSA AGENTS

1Learn-Han Lee*, 1Hooi-Leng Ser, 1Jodi Wean-Fei Law, 2Vengadesh Letchumanan, 3Kok-Gan Chan, 4Bey-Hing Goh, 5Nural-Syakima Ab Mutalib, 5Loh Teng-Hern Tan. 1Novel Bacteria and Drug Discovery (NBDD) Research Group, Microbiome and Bioresource Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia; 2Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Malaysia; 3Biofunctional Molecule Exploratory (BMEX) Research Group, School of Pharmacy, Monash University Malaysia, Malaysia; 4UKM Medical Molecular Biology Institute (UMBI), UKM Medical Centre, University Kebangsaan Malaysia, Malaysia; 5Clinical School Johor Bahru, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Malaysia

**Background** The genus Streptomyces is well-known for the production of numerous bioactive compounds with interesting chemical scaffolds. Streptomyces pluripotens MUSC 135T was isolated from a mangrove forest in Malaysia during a screening program for bioactive actinobacteria. The crude fermentative extract of MUSC 135T was shown to inhibit the growth of several pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Thus, this study aimed to explore the potentials of Streptomyces pluripotens in producing valuable bioactive compounds via fermentation experiments and genome mining to identify the presence of biosynthetic gene clusters (BGCs) for secondary metabolites.

**Methods** The genome mining analysis was performed by applying the anti-SMASH pipeline to annotate and analyze potential biosynthetic gene clusters of secondary metabolites in S. pluripotens. Gas chromatography-mass spectrometry (GC-MS) analysis was performed to detect the presence of bioactive compounds in the methanol extract of the fermentation product of Streptomyces pluripotens. Anti-colon cancer and anti-MRSA activities of identified bioactive compounds were evaluated.

**Results** GC-MS analysis detected several bioactive compounds that possess anti-colon cancer cells properties in the methanol extract of the fermentation product of Streptomyces pluripotens. For instance, compound (1) exhibits cytotoxic activity towards colorectal cancer HCT116 cell line (IDDF2021-ABS-0123 Figure 1. Streptomyces pluripotens MUSC 135T, a treasure trove for anti-colon cancer and anti-MRSA agents). The result of BGCs prediction revealed 28 putative biosynthetic gene clusters, 8 of them showed high similarity to known gene clusters (>80%). These predicted gene clusters were reported to encode compounds with promising anti-colon...
cancer properties, including ectoine, desferrioxamine B/E, and antimycin. Subsequently, one of the predicted genes from the LAPs gene cluster was selected and de novo synthesized for expression study using Escherichia coli model. In the anti-MRSA test, the purified protein Protein135 showed a minimum inhibitory concentration (MIC) of 3 μM against MRSA ATCC 33591 at 24-hour incubation. Intriguingly, Protein135 demonstrated higher growth inhibition than vancomycin, both at sub-MIC of 0.25 μM, against MRSA ATCC 33591.

Conclusions Altogether, these findings highlight the importance of novel strain from the mangrove forest, particularly in searching for beneficial bioactive compounds. In addition, our preliminary study unveils the promising wound healing property of Protein135 in the MRSA infection murine model.